» Articles » PMID: 34261889

Recommendations to Inform Substance Use Disorder Data Sharing Research: Scoping Review and Thematic Analysis

Overview
Journal J Addict Med
Specialty Psychiatry
Date 2021 Jul 15
PMID 34261889
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Title 42 Code of Federal Regulations Part 2 (42 CFR Part 2 or Part 2) was enacted in 1975 to protect patients receiving treatment for substance use disorders. A scoping review on Part 2 characterized published work.

Methods: Seven databases were searched. Studies were categorized based on date of publication, primary objectives, methods, and findings. A thematic analysis was conducted using article titles and abstracts.

Results: Of the 36 studies identified, the majority (78%) were opinions or legal reviews, (22%) employed quantitative and/or qualitative methods to study the impact of Part 2, and over half (58%) were published in the past 5 years. Only 8% of studies reported stakeholder involvement in Part 2 studies and no study included patients or patient advocates. No study discussed the efforts to align Part 2 with Health Insurance Portability and Accountability Act or provided evidence of the benefit of this alignment. Three main themes emerged from the review: care delivery (46.6%), law and ethics (27.6%), and technology (25.9%). There were no studies focusing on stigma and its effect on substance use treatment and Part 2.

Conclusions: Despite the significance of Part 2, the literature is sparse. It is time to initiate a new era of scholarly research that focuses on the impact of statutes and policies that govern substance use disorder data sharing. Specifically, we recommend research on Part 2 and Health Insurance Portability and Accountability Act alignment, the effects of Part 2 on patients, as well as providers and other stakeholder perceptions on the regulation.

Citing Articles

FHIR Granular Sensitive Data Segmentation.

Lee P, Mendoza D, Kaiser M, Lott E, Singh G, Grando A Appl Clin Inform. 2025; 16(1):156-166.

PMID: 39970944 PMC: 11839247. DOI: 10.1055/a-2466-4371.


Telemedicine-delivered treatment for substance use disorder: A scoping review.

Pham H, Lin C, Zhu Y, Clingan S, Lin L, Mooney L J Telemed Telecare. 2023; :1357633X231190945.

PMID: 37537907 PMC: 11444076. DOI: 10.1177/1357633X231190945.


Perceptions and Concerns of SUD Treatment Organizations Regarding the CARES Act's Alterations to Patient Confidentiality Regulations.

Ivanova J, Saks M, Karway G, Murcko A, Espino C, Millea C Perspect Health Inf Manag. 2022; 19(Spring):1b.

PMID: 35692851 PMC: 9123523.

References
1.
Manuel J, Newville H, Larios S, Sorensen J . Confidentiality protections versus collaborative care in the treatment of substance use disorders. Addict Sci Clin Pract. 2013; 8:13. PMC: 3766245. DOI: 10.1186/1940-0640-8-13. View

2.
Helms D . A guide to the new federal rules governing the confidentiality of alcohol and drug abuse patient records. Contemp Drug Probl. 1975; 4(3):259-83. View

3.
Wu L, Payne E, Roseman K, Case A, Nelson C, Lindblad R . Using a health information technology survey to explore the availability of addiction treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat. 2020; 112S:56-62. PMC: 7134339. DOI: 10.1016/j.jsat.2020.01.015. View

4.
Ernst D, Miller W, Rollnick S . Treating substance abuse in primary care: a demonstration project. Int J Integr Care. 2007; 7:e36. PMC: 2092396. DOI: 10.5334/ijic.213. View

5.
. Confidentiality of Substance Use Disorder Patient Records. Final rule. Fed Regist. 2017; 82(11):6052-127. View